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The most significant development in liver transplan-
tation in the USA over the past year was the full
implementation of the MELD- and PELD-based allo-
cation policy in March 2002, which shifted empha-
sis from waiting time within broad medical urgency
status to prioritization by risk of waiting list death.
The implementation of this system has led to a de-
crease in pretransplant mortality without increasing
post-transplant mortality, despite a higher severity of
illness at the time of transplant.
The trend over the last few years of rapidly increasing
numbers of adult living donor liver transplants was re-
versed in 2002 by a decline of more than 30% in the
number of these procedures. In 2002, a greater per-
centage of women received livers from living donors
(43%) than deceased donors (34%), possibly because
of size considerations.
From 1993 to 2001, the waiting list increased more than
sixfold, from 2902 patients to 18 047 patients. For the
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first time since 1993, the waiting list size decreased
in 2002, dropping 6% to 16 974 candidates. The per-
centage of temporarily inactive liver candidates also
increased from 2001, thus the net decrease in the ac-
tive waiting list for 2002 was 12%. This may reflect a
trend toward less pre-emptive listing practices under
MELD.
Intestine transplantation remains a low-volume pro-
cedure limited to a few transplant centers and
is still accompanied by significant pre- and post-
transplantation risks. As this procedure matures, its
application may increase to include recipients at an
earlier stage of their disease with better likelihood of
success.
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Introduction
Liver transplantation, like all solid organ transplantation, is
characterized by progressive disparity between supply and
demand, with ever increasing numbers of potential can-
didates and a significantly slower rise in the number of
donor organs available. Despite using organs from older
donors and donors with steatosis or evidence of current
(e.g. hepatitis C positive) or prior (e.g. hepatitis B core
antibody positive) viral hepatitis, the number of deceased
donor organs has increased slowly. This shortage led to a
marked increase in adult-to-adult living donor transplanta-
tion from 1998 to 2001. Although this trend was expected
to continue to grow as it has in renal transplantation, a
marked decrease in adult living donor transplants was seen
in 2002, with the number of procedures decreasing by ap-
proximately 50% back to the level seen in 2000 (1). This
trend probably reflects concerns about donor safety among
programs, potential donors, and recipients following highly
publicized adverse donor outcomes. Additionally, after sev-
eral years the majority of patients on existing transplant
waiting lists who were interested in and prepared for liv-
ing donor transplantation had already undergone the proce-
dure, thus leaving primarily the smaller pool of new listings
as potential living donor candidates.
Given the decrease in living donor transplants and a more
limited applicability of this modality than for renal trans-
plantation, the need to maximize the utility of deceased
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donor organs is paramount. In response to the HHS final
rule and the Institute of Medicine Report, the model for
end-stage liver disease and pediatric end-stage liver dis-
ease (MELD and PELD) scores for prioritization of adult
and pediatric liver transplant candidates were implemented
to replace the prior allocation scheme with an objective
severity-based allocation model. Initially designed to pre-
dict post-TIPS mortality, MELD was shown to be superior
to Child-Pugh classification at predicting short-term patient
mortality in diverse patient groups with end-stage liver dis-
ease, including transplant candidates. The system was fully
implemented at the end of March 2002, making 2002 the
first year to assess the impact of using the new allocation
system. This report contains the first significant data using
MELD/PELD, the implementation of which has resulted
in decreased pretransplant mortality and some important
shifts in which patients, particularly those with hepato-
cellular carcinoma, receive transplants. MELD and PELD
are also addressed in a companion article in this report,
‘Improving liver allocation: MELD and PELD’ (2). Waiting
list mortality, however, remains significant and has grown
over the last decade while post-transplant survival has im-
proved, making the survival benefit of transplant compared
to waiting even greater.
Intestine transplantation remains a lower-volume proce-
dure limited to a small number of centers and still accompa-
nied by high rates of death on the transplant waiting list and
high rates of graft failure and death post-transplantation.
It is hoped that continued advances in patient and donor
selection, as well as in immunosuppressive and perhaps
immune tolerance protocols, will continue the advances in
this field over the coming years.
Unless otherwise noted, the statistics in this article come
from reference tables in the 2003 OPTN/SRTR Annual
Report. Two companion articles in this report, ‘Trans-
plant data: sources, collection, and caveats’ and ‘Ana-
lytical approaches for transplant research’, explain the
methods of data collection, organization, and analysis that
serve as the basis for this article (3,4). Additional detail
on the methods of analysis may be found in the ref-
erence tables themselves or in the Technical Notes of
the OPTN/SRTR Annual Report, both available online at
http://www.ustransplant.org.
Liver Transplantation
Liver waiting list characteristics
As in other fields of solid organ transplantation, the gap be-
tween the number of patients listed as candidates for liver
transplantation and the number of transplants performed
has grown over the last 10 years (through 2001). The wait-
ing list increased more than sixfold in this time, from 2902
patients in 1993 to 18 047 patients in 2001 (Figure 1). The
waiting list decreased in 2002 for the first time, dropping
by 6% to a total of 16 974 patients waiting. The number
0
Source: 2003 OPTN/SRTR Annual Report, Table 9.1.






















Figure 1: Patients on the liver waiting list, 1993–2002.
of temporarily inactive patients increased (from 3109 pa-
tients in 2001 to 3866 in 2002), thus the net decrease in
the active waiting list for 2002 was 12%.
The pediatric liver transplant waiting list increased more
slowly over the last 10 years, from 427 patients listed in
1993 to 1079 in 2001, with a drop in 2002 to 955, a de-
crease mirrored in the overall list. The adult waiting list
grew more quickly during the last decade, therefore the
percentage of pediatric patients on the waiting list de-
creased to 6% in 2002 from 15% in 1993.
The racial distribution on the waiting list has remained un-
changed over the last 10 years. In 2002, 87% of the pa-
tients were white, while African-Americans represented
7% and Asians another 4%. There has been a rise in the
number of Hispanics on the waiting list from 11% in 1994
to 15% in 2002.
Male candidates continue to outnumber female candidates
on the waiting list. In 1993 male patients represented 53%
of all registrants; this proportion rose gradually to 57% in
2002. Blood type O continues to be more prevalent on the
waiting list than in the general US population. The distri-
bution of ABO blood types among candidates remained
unchanged over the last decade. In 2002, 51% of the pa-
tients had blood type O, 35% had blood type A, 11% had
blood type B, and 3% were blood type AB. US residents
represented 99% of the waiting list in 2002, and there was
no change over the last decade.
In 1993, 8% of registrants on the waiting list had received
a previous liver transplant. After a decline to 5% in 1999,
this proportion rose to 7% in 2001 and 2002. More im-
portantly, among such registrants, the proportion whose
relisting occurred less than 30 days from the date of the
prior transplant decreased from 31.9% in 1993 to a nadir of
15.6% in 1999, and then increased dramatically to 47.4%
in 2002 (Figure 2). The reasons underlying this recent trend
could include increased use of expanded criteria donor
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Figure 3: Patients waiting 2 years or more for a liver transplant.
livers and split livers, both of which have increased rates
of graft failure when compared to standard grafts (5–7).
Overall, the waiting time for liver transplantation continues
to increase (Figure 3). In 2002, 7857 out of 16 974 patients
on the waiting list (46%) were waiting more than 2 years,
compared with 7221 (40%) in 2001 and 424 (15%) in 1993.
Waiting time for patients transplanted in the 25th per-
centile, however, actually decreased in 2002, down from
193 days in 2000 to 80 days in 2002. This is due to the fact
that sicker patients have faster access to transplant under
MELD/PELD and that patients are no longer listed in order
to acquire waiting time.
Out of the 16 974 candidates listed for liver transplantation
at the end of 2002, 14 740 were listed according to the
MELD score, 686 (4%) according to the PELD score and
22 (0.1%) were Status 1. The vast majority of the adult pa-
tients with chronic liver disease (82%) had a MELD score
of 20 or less. These included 38% with a MELD score of
6–10 and 44% with a MELD score between 11 and 20. Pa-
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Figure 4: Tenth percentile of time to liver transplant by MELD and
PELD score, 2002.
MELD scores above 30 made up 0.6% of the total waiting
list. The pediatric patients on the waiting list had a similar
distribution, but more patients waiting were in the lower
PELD bracket; 77% of pediatric patients had a PELD score
of less than 11, 15% had a PELD score of 11–20, 6% had a
PELD score of 21–30 and only 2% had a PELD score above
30. The 10th percentile time to transplant for new waiting
list registrants varied according to MELD and PELD scores
and stage of hepatocellular carcinoma (median 82 days for
those with Stage T1 tumors vs. 36 days for patients with
Stage T2 tumors) (Figure 4). Implementation of the PELD
score reduced the 10th percentile of pediatric time to trans-
plant to 32 days for PELD scores less than 11, 21 days for
PELD of 11–20, 6 days for PELD of 21–30, and 5 days for
patients with PELD scores above 30.
Only 233 patients with hepatocellular carcinoma (1.4%)
were on the waiting list at the end of 2002. Of these
patients, 69 (0.4%) were staged T1 and 164 (1%) were
staged T2.
Waiting list registrations increased from 5535 in 1993 to
11 132 in 2001, and then dropped to 9651 in 2002. The
drop in waiting list registrations in the last year, which was
seen across all age groups, was 13% overall. It is likely that
decreased registrations are a result of the MELD system
and decreased importance assigned to waiting time in or-
gan allocation. Pediatric registrations were 8% of the total
in 2002. The number of registrations of patients less than
1 year old increased from 276 in 1993 to 409 in 2001, then
decreased to 349 in 2002. The number of registrations of
all other pediatric candidates decreased slightly from 481
in 1993 to 455 in 2002. In the adult population there was
an increase in registrations in all age groups, although this
was more sustained in patients 35 years or older. In 2002,
the 50–64 year age group had the most registrants (4297).
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New waiting list registrations increased by approximately
73% for both whites and African-Americans. There was an
increase in the listing of Asians from 170 in 1993 to 399 in
2002. Registration of Hispanics rose from 504 in 1993 to
1433 in 2002.
The number of annual registrations of female patients in-
creased by 50% over the period, from 2454 in 1993 to 3690
in 2002. Male patient registrations, however, increased by
93%, from 3081 in 1993 to 5961 in 2002, thus increasing
the male predominance on the waiting list.
As mentioned above, patients registered for liver trans-
plantation showed a distribution of blood types in which
type O candidates were more common on the waiting list
than in the US general population. Access to transplanta-
tion was better for type AB. The median waiting time for
liver transplantation for type AB was 136 days. The median
time exceeded 1 year in all other blood types. Out of 9477
registrations, 119 (1.3%) were nonUS residents. The abso-
lute number of registrations of nonUS residents dropped
by 30% compared with 2001.
In 2002, the median time from listing to transplant was
128 days for adults with a MELD score of 21–30 and
29 days for those with a MELD score of 31–40. In com-
parison, the median waiting time in 2001 for patients listed
with medical urgency Status 2A was 70 days and for Status
2B was 301 days.
Waiting time for children was shorter than for adults. The
median time from listing to transplantation was 243 days
for PELD scores of less than 11, 138 days with scores of
11–20, 125 days with PELD scores of 21–30, and 15 days
with PELD scores of 31 and above.
Registrations of patients with medical urgency Status 1 de-
creased by 25% from 678 in 1993 to 510 in 2002. Some of
this reflects a change in the eligibility criteria for Status 1
listing over time rather than trends in listing for acute hep-
atic failure in the earlier part of the study interval. In 2002,
the median waiting time to transplant was 11 days for pa-
tients in this category. The median waiting time to trans-
plant for patients with hepatocellular carcinoma in 2002
was 82 days with T1 tumors and 36 days with T2 tumors.
The number of deaths on the waiting list increased more
than threefold, from 579 in 1993 to 2034 in 2001. In 2002,
however, there was an 11% decrease in the number of
deaths to 1818 (Figure 5). A possible explanation for this
decline is the implementation of the MELD/PELD allocation
system that preferentially directs livers to patients with the
most imminent risk of death. The number of liver trans-
plants increased by 2% from 2001 to 2002. Until 2001,
however, the number of deaths on the waiting list con-
tinued to increase despite annual increases in the num-
ber of transplants performed—probably an impact of the
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Source: 2003 OPTN/SRTR Annual Report Table 9.3.
Figure 6: Death rate per 1000 patient years at risk, 1993–2002.
discussed in detail in the MELD/PELD article in this report
(2). In addition to a drop in the absolute number of deaths on
the liver waiting list, the rate of death continues to decline,
reflecting either continued improvements in pretransplant
care or a continued increase in the number of patients on
the waiting list with low short-term mortality risk (Figure 6).
Although the MELD/PELD system did not alter the alloca-
tion system for Status 1 patients, the mortality rate con-
tinued to fall for this group as well in 2002. The decline
in mortality rate for Status 1 patients occurred despite an
increase in the median time to transplant (Figure 7). This
suggests that the continued downward trend in waiting
list mortality may be related, in part, to improvements in
pretransplant care as well as to improved access to livers
for those with an urgent need for transplantation. Deaths
on the pediatric waiting list have been very low, reflecting
the intended design of the system, which predicts lower
mortality risk at any given PELD score compared with the
equivalent MELD score.
Another important waiting list trend is the dramatic decline
(the first ever) in the time to transplant for new waiting list
registrants. The 10th and 25th percentile of the time to
transplant for new liver registrants fell from 29 days and
169 days in 2001 to 14 and 80 days, respectively, in 2002.















Source: 2003 OPTN/SRTR Annual Report, Tables 9.2, 9.3.






































Time to Transplant Death Rate
Figure 7: Waiting list death rates per 1000 patient years at risk
and time to transplant for Status 1 liver patients, 1993–2002.
Again, this is probably an effect of the MELD allocation
system, because patients who are listed when they are
very ill no longer have to accrue substantial waiting time
before being allocated a liver, and patients are no longer
being listed simply to accrue waiting time.
Overall annual death rates per 1000 patient years at risk
dropped progressively from 225 in 1993 to 119 in 2001
and 106 in 2002. Infants less than 1 year old, however,
show a progressive increase in mortality over time. Annual
death rates per 1000 patient years at risk increased from
502 in 1993 to 572 in 2001 and 766 in 2002. In all other
age groups the annual death rates per 1000 patient years
at risk have decreased by more than half during the last
decade.
In 2002, the annual death rate per 1000 patient years at
risk was highest for African-Americans (153), followed by
whites (103), then Asians (84). Hispanics had 113 deaths
per 1000 patient years at risk. There was no difference
in death rates between female and male patients on the
waiting list (101 and 109, respectively). The annual death
rates per 1000 patient years at risk varied minimally by
blood type: 108 for type O, 100 for type A, 119 for type B
and 95 for type AB.
The annual death rate per 1000 patient years at risk was
higher in patient groups with higher MELD scores, as ex-
pected. The annual death rates per 1000 patient years at
risk in 2002 were 52 in patients with MELD scores of
6–10, 121 in patients with scores of 11–20, 666 in patients
with scores of 21–30, and 3029 for patients with MELD
scores of 30 and above. This has been seen despite the
fact that the waiting time for transplant was much shorter
in the higher MELD score groups and reflects the ability of
MELD to predict short-term mortality accurately. The risk of
death on the waiting list by MELD still varies by region and
blood type. Although organ distribution issues remain con-
troversial, future research is needed to attempt to equalize
the risk of dying on the waiting list.
Patients on the waiting list with hepatocellular carcinoma
had a higher annual death rate per 1000 patient years at risk
in 2002, with 163 for T1 tumors and 165 for T2 tumors.
Liver transplant recipient characteristics
There has been a steady increase each year in the number
of liver transplants being performed with deceased donor
organs, from 3399 in 1993 to 4962 in 2002. Several fac-
tors have contributed to this: more patients on the waiting
list, an increase in the number of deceased donors, and
the use of expanded donor livers (8). In 2002, 5369 livers
were recovered from 6182 deceased donors (Figure 8),
meaning 87% of deceased donors were liver donors; how-
ever, 407 (8%) of these livers were discarded, so ultimately
80% (4962/6182) of the deceased donor livers were trans-
planted. The number of transplants in recipients younger
than 18 years was similar in 2001 and 2002, with virtually
all of the increase in the number of transplants occurring
in the age groups 35–49, 50–64, and older than 65 years,
a steady trend over the past decade. The majority of pa-
tients transplanted (53%) were 50 years or older. Most of
the patients transplanted in 2002 were 50–64 years old
(46.2%), and 7% were 65 years or older. The percentage
of recipients aged 50–64 years rose from 37% in 1993 to
46% in 2002. The increasing age trend in transplant recip-
ients most likely reflects the growing number of older pa-
tients on the waiting list, which is multifactorial, including
increased willingness of centers to transplant older individ-
uals, longer waiting times, and the increasing median age
of the hepatitis C cohort, which was largely infected in the
1960s and 1970s.
Recipient race was 83% white, 10% African-American, 4%
Asian, and 3% other/multiracial. These percentages are
similar to the characteristics of the waiting list patients, of
whom 87% were white, 7% African-American, 4% Asian,
and 2% other/multiracial (Figure 9). Ethnicity was similar
between the waiting list patients and transplant recipients
for the Hispanic/Latino population (15% and 13%, respec-
tively) and for the non-Hispanic/non-Latino population (84%








































Source: 2003 OPTN/SRTR Annual Report, Table 1.1
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Figure 8: Deceased and living liver donors, 1993–2002.
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Figure 9: Liver waiting list and transplants by race, 2002.
decreased from 86% in 1993 to 83% in 2002, with a con-
current rise in African-American recipients from 8.7% to
9.6% and in Asians from 2.6% to 4.3%. The proportion of
patients of Hispanic ethnicity increased from 10% to 13%.
There continued to be a trend towards a greater percentage
of men being transplanted (66% in 2002); this may reflect
the distribution of diseases between men and women, dis-
ease severity, and size considerations. The blood type dis-
tribution for recipients in 2002 was type O 42%, type A
39%, type B 13%, and type AB 6%. This matches the
overall estimates of blood types in the US population (and
thus the donor population) and has not changed since 1993.
The percentage of blood type O among recipients is lower
than that of the patients waiting for transplantation. Ap-
proximately 9% of liver transplant recipients in 2002 had
undergone a prior liver transplant, the lowest percentage
to date, down from 17% in 1993 and 10% in 2001. The
absolute number of retransplantation procedures was 571
in 1993 and has since remained between 425 and 467 per
year. US residents made up 99% of the recipients.
The MELD/PELD system of recipient prioritization was
implemented on February 27, 2002, so that data from
2002 includes transplant recipients transplanted under the
MELD/PELD system (n = 3830, or 77%) and the old
Status 2, 2A, 2B, 3, and 7 system (n = 652, or 13%).
The Status 1 system was unaffected by MELD/PELD,
and 480 (10%) Status 1 patients were transplanted in
2002, compared with 601 in 2001. In 2002, ‘not hospital-
ized’, ‘hospitalized’, and ‘in intensive care unit’ (ICU) re-
cipients made up 69%, 15%, and 15%, of the total, re-
spectively, with the most substantial change being a de-
crease in the ICU-bound recipients from 27% in 2001 to
15% in 2002 (a relatively steady decrease over the past
decade). Only 7% of recipients were on life support at
transplant, compared with 11% in 2001. One of the antic-
ipated benefits of the MELD/PELD system is that sicker
patients will be transplanted before they progress to a
more grave ICU-bound status. This was seen in New Eng-
land, where implementation of a point system based on
disease severity prior to MELD/PELD resulted in the sicker
2B patients being transplanted before they progressed
to 2A (9). Of note was the increase in the ‘not hospital-
ized’ recipients, from 58% in 2001 to 69% in 2002. This
trend is probably multifactorial, resulting from a higher per-
centage of stable hepatocellular carcinoma patients trans-
planted after implementation of the MELD/PELD system,
decreased severity of illness due to pre-emptive trans-
plantation, improved pretransplant care, and decreased
use of the ICU to maintain patient medical urgency sta-
tus. Whether these trends will continue remains to be
seen. The MELD scores at which adult recipients re-
ceived transplants in 2002 included the following percent-
ages: 6–10 (4%), 11–20 (24%), 21–30 (15%), and >30
(10%). The PELD scores for children included the follow-
ing percentages: <11 (1.7%), 11–20 (1.1%), 21–30 (0.7%),
>30 (0.1%). Patients with hepatocellular carcinoma T1
tumors made up 2.7%, hepatocellular carcinoma T2 tu-
mors 13.3%, other exceptions 5.5%, and Status 1 9.7%.
The remaining 13.1% were transplanted under the old
medical urgency status system during the first 2 months
of 2002.
The primary diagnosis groups of deceased donor liver
transplant recipients in 2002 included noncholestatic cir-
rhosis as the most common (61%), followed by cholestatic
liver disease/cirrhosis (10%), acute hepatic necrosis (8%),
biliary atresia (3%), metabolic diseases (3%), malignant
neoplasms (7%, compared with 3.5% in 2001), and other
(8%). According to additional SRTR analysis, the frequency
of hepatitis C as the primary diagnosis for transplant recip-
ients has grown over the past decade, from 21% in 1993
to 31% in 2002.
The spectrum of liver disease etiology has gradually
changed over the last decade. The absolute number of pa-
tients with cholestatic liver disease transplanted decreased
from 594 (18%) in 1993 to 485 (10%) in 2002, parallel to
an increase in the number of transplants for noncholestatic
liver disease from 1959 patients (58%) in 1993 to 3004
(61%) in 2002. Acute hepatic necrosis increased from 218
cases in 1993 to 441 in 2000, but since then, the number of
transplants performed for this etiology has declined to 388
(12%). Increased waiting time may play a role in this trend
with an increased proportion of patients with acute liver
failure who either recover or develop contraindications to
transplantation.
Between 2.7% and 3.5% of transplants were per-
formed for malignancy between 1993 and 2001. Under
MELD/PELD in 2002, the number of transplants for malig-
nancy increased more than twofold, but still represented
only 7% of the transplants performed. There was a grad-
ual decrease in the number of patients with biliary atresia
transplanted, from 240 in 1993 (7%) to 164 in 2002 (3%).
The incidence of liver transplantation steadily increased
from 13 per million population in 1993 to 18 in 2002. The
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highest incidence was seen in recipients aged 50–64 years
(54 per million), which was consistent across racial and
ethnic groups.
There was a steady increase in living donor liver trans-
plants, from 36 in 1993 to 84 in 1997. A more rapid increase
occurred from 92 in 1998 to 511 in 2001, primarily because
of an increase in adult living donor liver transplants; 97%
of living donor recipients were younger than 18 years in
1997 compared with 20% in 2002 (Figure 10). A decrease
to 358, however, was noted in 2002. This sharp decrease
in living donor liver transplants may have been related to
increased concern about donor safety after a widely pub-
licized donor death, as well as published reports of sig-
nificant donor morbidity and mortality (10,11). Recipient
race and ethnicity were similar to deceased donor trans-
plants, but there was a trend in 2002 towards a greater
percentage of women receiving living donor liver trans-
plants (43%) compared with deceased donors (34%), pos-
sibly because of size considerations. A greater proportion
of living donor recipients were blood type O (55%) com-
pared with deceased donors (42%), probably reflecting the
markedly longer waiting times for deceased donor organs
among blood type O candidates and a tendency, there-
fore, to opt for living donor transplantation. Only 2% of
recipients were retransplants, and 2% were nonUS resi-
dents. There was a trend towards living donor recipients
being less ill: 79% were not hospitalized compared with
69% for deceased donor recipients, and only 8% were in
an ICU compared with 15% of deceased donor recipients.
Similarly, the MELD scores for the adult recipients were
lower: 6–10 (14%), 11–20 (41%), 21–30 (3.9%). Further-
more, fewer patients were transplanted for hepatocellular
carcinoma (1.4% T1 and 0.8% T2), probably due to the
increased points received by HCC patients after the imple-
mentation of the MELD system. PELD scores for pediatric
living donor recipients were: <11 (5%), 11–20 (3%), 21–30
(2%), and >30 (0.3%). The primary diagnoses were simi-
lar to deceased donor recipients except for a slight trend
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Figure 11: Relationship of living liver donors and recipients, 2002.
lignant neoplasms in the living donor recipients. Parents
made up 15% of donors, offspring 25%, siblings 20%,
other relatives 10%, spouse 5%, and other unrelated 17%
(Figure 11). The increase in unrelated donors has occurred
since the introduction of adult-to-adult living donor liver
transplant despite the risks to the donors. This increase
undoubtedly reflects the tremendous pressures that the
shortage of deceased donor livers and long waiting times
are putting on patients and their friends and relatives.
Liver transplant patient survival
Unadjusted patient survival among deceased donor liver
transplant recipients was 92% at 3 months, 86% at 1 year,
78% at 3 years, and 72% at 5 years post-transplant.
Among living donor transplant recipients, unadjusted sur-
vival was slightly higher at all time points except 3 years
post-transplant (Figure 12). Differences in unadjusted pa-
tient survival between groups of patients at each time pe-
riod were significant at p ≤ 0.05 for comparisons based
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are for transplants performed during 2000-2001 for 3 months & 1
year; 1998-1999 for 3 year; and 1996-1997 for 5 year survival
Time after Transplant












Figure 12: Unadjusted patient survival among liver transplant re-
cipients, living vs. deceased donor.
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status, and donor age. Adjusted 1-year deceased donor pa-
tient survival (adjusted for population parameters in 2001)
increased from 83% in 1992 to 88% in 2001.
Patient survival for deceased donor recipients varied sig-
nificantly with recipient age. Five-year survival was 84%
in the 6–10 year old group but only 62% in recipients
over 65 years of age. African-American patient survival
was 2–5% lower than that of whites at each of the time
intervals. Patient survival was similar by ethnicity and
gender. Patients transplanted from the ICU had a lower
post-transplant survival when compared with patients who
came in from home, a difference seen in both short-term
and long-term survival. The difference in survival was 7%
at 3 months, 9% at 1 year, 11% at 3 years, and 9% at
5 years. Patients on life support before transplantation had
an 80% survival at 3 months and 63% at 5 years, which
was 13% and 10% lower, respectively, than for those who
were not on life support (p < 0.0001).
Patient survival also varied based on etiology of liver dis-
ease (Figure 13). Five-year patient survival was worst
for malignancy (59%). Acute hepatic necrosis (69%) and
noncholestatic liver diseases (70%) were an intermediate
group. The best survival rates were seen with metabolic
liver disease (80%), biliary atresia (80%), and cholestatic
liver disease (81%). These differences are related to two
factors: (i) severity and recurrence of disease and (ii) age
differences in the recipients.
The volume of liver transplants performed per center did
not influence the unadjusted patient survival at all time
intervals to 5 years post-transplant. Donor age above
65 years was associated with a lower patient survival (90%
at 3 months, 61% at 5 years).
The overall annual death rate per 1000 patient years at risk
post-transplant decreased from 244 in 1993 to 163 in 2001












Source: 2003 OPTN/SRTR Annual Report, Table 9.11. Cohorts for





























Figure 13: Five year unadjusted patient survival among liver trans-
plant recipients, by diagnosis.
age. In 2002, the annual death rate per 1000 patient years at
risk in the first year post-transplant was 279 in infants under
1 year of age, a marked reduction from the corresponding
figure in 1993 (1060), and was 181 in patients older than
65 years.
The annual death rate per 1000 patient years at risk in the
first year post-transplant was moderately different by eth-
nicity and race: 128 for Hispanics, 145 for whites, 146 for
African-Americans, and 164 for Asians. African-American
patient survival was 2–5% lower than that of whites at
each of the time intervals (p < 0.05 for each year). The risk
of death post-transplant was also similar among different
blood types. The risk almost tripled if the recipient had any
previous solid organ transplant (337 vs. 130 after primary
transplants).
In 2002, for the first year following transplant, recipients
who underwent transplant from the ICU had an annual
death rate per 1000 patient years that was 2.5 times higher
than that of patients who came from home. In 1993, the
corresponding difference in death rate between patients
receiving transplant from the ICU vs. from home was 3.1.
The overall risk for patients in the ICU has decreased by
54%, from 485 in 1993 to 263 in 2002. Similarly, patients
on life support before transplant had a threefold higher an-
nual death rate per 1000 patient years at risk in the first
year than those who were not. Despite the improvements
in care seen over the last decade, the higher risk of death
experienced by patients on life support has changed little
over the decade.
In 2002, the annual death rate per 1000 patient years at
risk in the first year post-transplant was highest for pa-
tients with acute hepatic necrosis (229) and malignancy
(203), followed by those with noncholestatic liver diseases
(143), cholestatic liver diseases (96), metabolic liver dis-
eases (77), and biliary atresia (74). This raises the ques-
tion as to whether most malignancies are recurring early
post-transplant.
There was an overall trend of improvement in the annual
death rate per 1000 patient years at risk in the first year
post-transplant for all of the former medical urgency status
groups: Status 1 patients (452 in 1993 to 257 in 2002),
Status 2A (387 in 1997 to 160 in 2002), Status 2B (456 in
1997 to 100 in 2002), and Status 3 (115 in 1997 to 63 in
2002).
Liver transplant graft survival
Graft survival after deceased donor liver transplantation
was 87% at 3 months, 81% at 1 year, 72% at 3 years, and
64% at 5 years post-transplant. Unadjusted living donor
recipient graft survival was slightly lower at all time points
except 5 years post-transplant (Figure 14). The 1-year ad-
justed deceased donor recipient graft survival increased
from 72% in 1992 to 81% in 2001.
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Source: 2003 OPTN/SRTR Annual Report, Table 9.8. Cohorts
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Figure 14: Unadjusted graft survival among liver transplant recip-
ients, living vs. deceased donor.
African-Americans tended to have worse graft survival than
the white patient population. The gap has been 2–6% each
year and has tended to increase. There was no difference
in graft survival between Hispanics and non-Hispanics or
between male and female patients.
Notably, patients with blood type AB had graft survival
4–6% higher than the patients with other blood types at
the 3-month interval. Patients who underwent retransplan-
tation had 18–21% lower graft survival than those who un-
derwent primary transplantation.
In terms of severity of illness, there was a difference
in graft survival among patients who came to transplant
from home, those who were in the hospital, and those
who were in the ICU. Patients who were in the ICU had
12–14% worse graft survival than those who came from
home. Three-month graft survival was 79% for patients
transplanted from the ICU and 91% for those who came
from home. This difference was maintained over time;
5-year graft survival rates were 56% and 69%, respec-
tively. Donor age was also associated with differing effects
on graft survival, especially at the extremes of age. For
donors younger than 1 year, 3-month graft survival was
77% and 5-year graft survival was 61%. The best graft sur-
vival was seen with donors aged 11–17 years (89% and
70%, respectively). Among donors of adult age, graft sur-
vival declined as age increased. Graft survival was 82% at
3 months and 51% at 5 years post-transplant using organs
from donors aged 65 years or older. These graft survival
statistics by donor age are not adjusted for other factors,
therefore the potential confounding effects of various re-
cipient selection factors are not apparent. However, the
separate results by donor age and recipient disease sever-
ity highlight the increased risk of placing the most marginal
grafts (e.g. from donors older than 60 years) into ICU-bound
patients on life support. Differences in unadjusted graft
survival between groups of patients at each time period
were significant at p ≤ 0.05 for comparisons based on race,
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Figure 15: Prevalence of people living with a functioning liver
transplant, 1993–2002.
Prevalence of liver transplant patients with
functioning grafts
Given the overall success of liver transplantation, the preva-
lence of people living with a functioning liver graft in the
USA increased gradually from 10 141 in 1993 to 31 195 in
2002 (Figure 15). In 2002, 27 138 were white, 2532 were
African-American, and 981 were Asian. The prevalence of
patients with functioning grafts allows one to study trends
over time for both incidence and outcome, although the
figures are more heavily weighted towards recent trans-
plants, because a higher proportion of recent transplant
recipients will be alive.
The proportion of patients with functioning liver transplants
who were African-American increased from 7.7% in 1993
to 8.1% in 2002, Asians increased from 2.1% to 3.1%
and whites decreased from 88.7% to 87.0%. The Hispanic
proportion increased from 9% to 11%. This probably re-
flects improved access to transplantation over time, rather
than improved outcomes in these racial and ethnic groups.
Among patients living with a liver graft, 59% were male
and 41% were female. Blood type distribution was similar
to the general population, which reflects the donor blood
type distribution and not the distribution on the waiting
list.
At the end of 2002, a total of 29 859 recipients of de-
ceased donor grafts were living, as were 1336 recipients
of living donor grafts. Among patients with a functioning
graft, 57% had been transplanted for noncholestatic liver
disease, 15% for cholestatic liver disease, 8% for acute
hepatic necrosis, 6% for biliary atresia, 5% for metabolic
disease, and 3% for malignancy. Living retransplant recip-
ients accounted for 8% of the total.
Distribution by medical urgency status at transplant was as
expected, given the relative rates of these transplants and
their relative survival; 63% came to transplant from home,
18% were in hospital, and another 19% were in the ICU.
For these patients, 9% had been on life support before
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transplant and 3934 patients (13%) had been transplanted
as Status 1.
Intestine
Intestinal failure, due either to loss or nonfunction of the
gastrointestinal tract, can be a pernicious disorder often re-
sulting in disability or death of the patient. Intestinal trans-
plantation was proposed as a treatment for those patients
who had life-threatening complications of total parenteral
nutrition (TPN), particularly TPN-related liver disease. Dur-
ing the past 15 years, organ replacement therapy in the
form of liver, liver/small bowel, and isolated small bowel
transplantation has been used as a lifesaving tool for pa-
tients who have failed TPN therapy.
Approval by the Centers for Medicare and Medicaid Ser-
vices (CMS) for reimbursement of intestinal transplanta-
tion was the most important governmental change in the
field of intestinal transplantation in 2002. CMS approval is
often the yardstick that third party payers use to determine
if a new procedure is investigational or experimental. One
of the major obstacles to access to intestinal transplanta-
tion has been financial. While some commercial carriers
were providing this service to their policy holders, many
carriers and state Medicaid agencies were not. As a conse-
quence of the CMS findings, more patients were provided
an opportunity to be considered for intestinal transplanta-
tion. There were no major OPTN policy changes in 2002
regarding this procedure, but the stage had been set for
changes to occur in 2003. Specifically, efforts were be-
ing made to provide extra MELD/PELD points to patients
with intestinal failure. In 2003, the OPTN approved a policy
change that encouraged regional review boards to allow
patients on the waiting list for combined liver/small bowel
transplant to receive an extra 12 MELD/PELD points. 2004
will probably see further developments in this area.
Intestine waiting list characteristics
The number of patients listed for intestinal transplanta-
tion has gradually increased since 1993, with the excep-
tion of a 9% reduction in patient registrations in 2002. At
the end of 2002, however, there were more patients listed
for intestinal transplant compared with 2001 (Figure 16).
The age of the patients awaiting intestinal transplants was
weighted heavily toward children (73%). Children less than
6 years of age represented 51% of the list. Race and eth-
nicity were characterized predominately as white and non-
Hispanic/non-Latino, respectively. There were many more
males than females listed, and the predominant blood type
was O. Prior transplant had been performed in 9% of pa-
tients, with the majority having undergone prior intestinal
transplantation (7%).
Intestine time to transplant
Nearly one-third of patients awaiting intestinal transplants
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Source: 2003 OPTN/SRTR Annual Report, Table 10.2

















Figure 17: Median time to intestine transplant, 1995–2002.
waited at least 6 months. The median time to transplant
was 310 days in 2002 and was slightly less than in 2001
(Figure 17). Children tended to have longer waiting times
than adults. The median time to transplant based on race
did not differ among white, Asian and other/multirace can-
didates. Follow-up was insufficient to evaluate the African-
American and Hispanic/Latino groups. Neither prior trans-
plant nor blood type appeared to have a major effect on
waiting time. The only exception to this was blood type
AB, which had a median time to transplant of only 44 days.
Intestine waiting list deaths
Reported deaths and annual death rates per 1000 pa-
tient years at risk have fluctuated over the past 10 years
(Figure 18). In 2002, there were 363 patients at risk for
death on the waiting list; this was a modest increase from
342 in 2001 and a sixfold increase from the 58 patients
at risk in 1993. The death rate for all patients waiting for
intestinal transplants in 2002 was 298. This rate is much
higher than that of any other transplant group (e.g. heart-
lung is 185). Despite considerable variability over the years,
the age group at greatest risk comprises those patients
younger than 1 year. Factors that contribute to this high
number include the need for size compatible donor organs
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Figure 18: Death rate per 1000 patient years at risk on the intes-
tine waiting list, 1993–2002.
(typically 25% smaller) and donor cytomegalovirus sero-
logic status. A review of other demographic factors, such
as race, ethnicity, and gender, has failed to demonstrate
any differences. Blood type B did have an apparent effect,
with a reported death rate of over 500 compared with 251
and 267 for blood types O and A, respectively. Currently
efforts are being made to change organ allocation pol-
icy to improve candidates’ opportunity to receive intestine
transplants.
Intestine transplant recipient characteristics
The number of intestinal transplant recipients did not
change considerably from 2001 to 2002. Children con-
tinue to make up the majority of the recipients, particu-
larly those younger than 5 years. Recipient demographics
including race, ethnicity, and gender did not differ from
the general population. In contrast, a far greater propor-
tion of blood type A patients received an organ transplant
than is reflected in the general population. In 2002 twice as
many patients underwent an intestinal retransplant as did
in the previous year. This rise probably reflects the grow-
ing number of recipients who have returned to the wait-
ing list after allograft failure. The degree of medical acu-
ity has changed since 2001, but remains similar to years
prior to that. In 1999, 2000, and 2002 approximately half of
the recipients were not hospitalized when called for trans-
plant. In 2001 more than two-thirds of patients were called
in from home. Reflecting the tenuous condition of these
patients, 14% were in the ICU at time of transplant. The
most common cause of intestinal failure requiring trans-
plant in the USA is short bowel syndrome followed by
functional bowel disorders, such as chronic idiopathic in-
testinal pseudo-obstruction (12). The prevalence of these
causes of intestinal failure is reflected in the pretransplant
diagnoses of the recipients.
Intestine transplantation—post-transplant death
rates
In 2002, the annual death rate per 1000 patients years at
risk during the first post-transplant year was 318, which
was lower than reported in 2001 (482). In 2001, children
aged 1–5 years were at greatest risk (791); fortunately, this
group demonstrated considerable improvement (384) in
2002. The small number of patients probably accounts for
much of the variability. Many of the age groups had such
small numbers of patients that interpretation was not pos-
sible. Race, gender, and ethnicity did not seem to play a
large role in death rates. Analysis of blood groups suggests
a higher survival for blood type B, but, again, this involved
very small numbers of patients. The most profound effect
on annual death rates was in the group who had a prior
transplant. Nearly one-half of the patients in this group died
in the first year. The prior transplant was typically either an
isolated small bowel transplant or a liver transplant.
A number of other variables can affect the post-transplant
death rates, including condition of the patient, underlying
diagnosis, and donor age. The condition of the patient was
categorized into one of three groups: on life support, in the
ICU, or hospitalized/at home. The numbers of patients on
life support were too small to calculate an annual death
rate. In 2000, however, patients transplanted from the in-
tensive care unit had a threefold higher death rate com-
pared with patients on a general ward in the hospital, and
an almost twelvefold higher death rate when compared
with patients coming from home. The primary diagnosis
had a modest effect on survival, with short gut syndrome
associated with about a 40% lower death rate when com-
pared with patients with functional bowel problems. Donor
age demonstrated wide variability within the various age
groups examined.
Intestine transplantation—graft survival and function
Adjusted graft survival was determined at four time points
following transplantation: 3 months, 1 year, 3 years, and
5 years. Sixty-four per cent of patients had a functioning
allograft at 1 year, but this number was only 33% at 5 years
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Figure 19: Adjusted graft vs. patient survival among intestine
transplant recipients.
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race, gender or primary diagnosis. This reflects the small
number of patients in the various groups. Patients who
underwent retransplantation had by far the worst outcome.
Neither center volume nor donor age had a major effect on
graft survival.
All organ replacement therapies seek first to save patient
lives but also to provide organs that function adequately.
For intestinal transplantation, adequate function would be
represented by freedom from TPN. As of 2002 there were
299 patients with functioning intestinal allograft. Children
aged 1–5 years represented the largest group (31%) with a
functioning allograft. No long-term effect on graft function
could be seen based on pretransplant diagnosis.
Intestine transplant patient survival
Patient survival rates at 3 months, 1 year, 3 years, and
5 years following intestine transplantation were 85%,
74%, 59%, and 50%, respectively (Figure 19). The very
young and very old appeared to fair worse in both short- and
long-term follow-up. The greatest success was achieved
in the 18–34 year age range in adjusted survival, a differ-
ence not found in the unadjusted analysis. Where adequate
data were available, no major differences could be seen
based gender or ethnicity. Racial differences were evident
between whites and African-Americans at all time points.
Recipient blood type did not influence survival in the short
term, but some differences did appear at the 5-year mark.
Blood type B had the best survival, while blood type AB
fared the worst, although the limited number of patients
makes this finding difficult to interpret. Primary diagnosis
had no effect on patient survival, whereas the retransplant
group was poorly represented and no data were available.
A negative center effect could only be seen in programs
that performed only one transplant per year.
Summary
The most significant development in liver transplantation
in the USA over the past year was the full implementation
of MELD- and PELD-based allocation, which has shifted
emphasis from waiting time within broad medical urgency
status to one based on prioritization by risk of waiting list
death. The implementation of this system has led to a de-
crease in pretransplant mortality without increasing post-
transplant mortality, despite a higher severity of illness at
the time of transplant. Over the next few years, the focus
will shift to refining and improving the model to limit the
need for exception and regional review boards, as well as
addressing disparities in organ distribution and incorporat-
ing post-transplant outcomes. The trend over the last few
years of rapidly increasing numbers of living donor trans-
plants has stabilized or declined, with a reduction in these
procedures in adults in 2002. Living donor transplants ac-
count for less than 10% of all liver transplants, in contrast
to kidney transplantation in which the number of living
donor and deceased donor grafts are nearly matched. Con-
cerns about living donor safety, early graft survival, and, at
present, limited applicability to critically ill patients has de-
creased the use of this procedure. It is hoped that new
data showing the benefit of living donor liver transplanta-
tion on waiting list mortality, along with further refinement
in donor and recipient selection, will allow ongoing growth
of this procedure and added benefit for all patients await-
ing liver transplantation (13). Intestinal transplantation re-
mains a low-volume procedure limited to a few transplant
centers, and like liver transplantation in its early days, it is
still fraught with both pre- and post-transplant risks. As this
procedure matures, its application will probably increase to
include recipients at an earlier stage of disease and with
better likelihood of success.
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